The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 8844 of March 02, 2023, Tuscany Regional Healthcare has published assessments of four medical devices in the cardiovascular and neurovascular treatment areas.
Below are the technologies that have been assessed:
- Intra-aortic occlusion device IntraClude by EDWARDS for patients undergoing endoscopic minimally invasive cardiac surgery with cardiopulmonary bypass;
- TactiFlex Ablation Catheter Sensor Enabled by Abbott for patients suffering from complex cardiac arrhythmias;
- Cerebral embolic protection device TriGUARD 3 by Keystone Heart for patients undergoing cardiac catheterization procedures to reduce the risk of cerebral embolism;
- Geometric thrombectomy system for the extraction of tough clots CERENOVUS NIMBUS by NEURAVI for patients with acute ischemic stroke due to neurovascular occlusion of large vessels and associated with resistance to mechanical thrombectomy.
See the regional decree and all assessments in Italian here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.